Press

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in Covid-19

Feb 14 • 3 min read

Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral…

HAVN Life Enters into Distribution Agreement with Mycrodose Therapeutics for U.S. Market

Feb 12 • 5 min read

HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) a biotechnology company pursuing standardized extraction of psychedelic compounds for investigational research as potential APIs to support brain health and cognitive function, is thrilled to announce its entry into an exclusive U.S. Distribution Agreement (the “Exclusive Distribution Agreement”) with California-based Mycrodose Therapeutics Inc. (“Mycrodose”), a leading pharmaceutical company in the…

Elemental Advisors Launches PSYK ETF Focused on the Medical Psychedelics Industry

Feb 10 • 2 min read

Elemental Advisors Inc. is pleased to announce the launch of PSYK ETF (NYSE: PSYK), a thematic ETF that tracks the performance of the Enhanced Consciousness Index (the “Index”), which is principally comprised of companies involved in the research, development, production and/or use of psychedelics to address medical conditions in legal pharmacological applications under the applicable…

Ehave Expands Its KetaDASH Brand And Begins Producing Revenue With The Purchase Of California Based Rejuv IV

Feb 9 • 3 min read

Ehave, Inc. (OTC Pink: EHVVF), a leading healthcare services and technology company, reaffirms its commitment to shareholders to launch its KetaDASH brand by completing the purchase of 100% of Rejuv IV. Rejuv IV provides mobile IV therapy in the San Francisco Bay Area, 7 days a week with flexible scheduling. Rejuv IV provides Ketamine treatments, as well…

Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada

Feb 8 • 3 min read

Mydecine Innovations Group Inc. (NEO: MYCO), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced that Health Canada has included the dealer’s license Mydecine operates under as a supplier for the Special Access Program, which allows healthcare providers to request specific drugs for approved patients who have not responded to…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441